Multiple innovative pharmaceutical companies are competing to accelerate the development of ADC drugs.

On the evening of December 24th, Hansoh Pharmaceutical announced that recently, the company and its subsidiary Shanghai Hansoh Pharmaceutical Co., Ltd. Injection SHR-A1904 has been included in the list of breakthrough therapeutic varieties by the Drug Evaluation Center of the National Medical Products Administration. It is understood that Injection SHR-A1904 is a monoclonal antibody drug conjugate targeting Claudin18.2 independently developed by Hansoh Pharmaceutical with intellectual property rights. It is worth noting that recently, many innovative drug companies such as Kangning Jerry, Bailing Tianheng, and Colenbo Tai have accelerated breakthroughs in the field of ADC research and development and made new progress. Industry insiders believe that in the global wave of ADC drug research and development innovation, Chinese companies have become the global ADC innovation engine and are expected to benefit in the long term. ADC drugs, as a revolutionary therapy in the field of cancer treatment, have great market growth potential.